Lamivudine News and Research

RSS
WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

New WHO guidelines recommend earlier treatment for people living with HIV

New WHO guidelines recommend earlier treatment for people living with HIV

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

CIHR, CMAJ honour five Canadians for health research excellence

CIHR, CMAJ honour five Canadians for health research excellence

Patients with drug-resistant HIV can safely achieve viral suppression without NRTIs

Patients with drug-resistant HIV can safely achieve viral suppression without NRTIs

Discovery provides clues for potentially eliminating HIV infection in children

Discovery provides clues for potentially eliminating HIV infection in children

Study highlights long-term benefits of early antiretroviral therapy initiated in infants

Study highlights long-term benefits of early antiretroviral therapy initiated in infants

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Combination regimens trump monotherapy in fight against HIV transmission

Combination regimens trump monotherapy in fight against HIV transmission

FDA ADAC recommends approval of Gilead’s Truvada for HIV

FDA ADAC recommends approval of Gilead’s Truvada for HIV

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1